Cu-ATSM [Cu-diacetyl-bis(N⁴-methylthiosemicarbazone)] is a small molecule chelate of radioactive Cu with ATSM ligand, and has been developed as a radiopharmaceutical for positron-emission tomography (PET) imaging to detect hypoxic regions in tumors. Among the radioactive Cu, ⁶⁴Cu has a unique feature that it emits not only positron for PET imaging, but also β⁻ particles and Auger electrons that can damage tumor cells. Therefore, ⁶⁴Cu-ATSM can be developed as an internal radiotherapy agent against tumors. Particularly for malignant brain tumors, a clinical PET study has reported that Cu-ATSM shows high tumor accumulation; and a non-clinical study has demonstrated that ⁶⁴Cu-ATSM treatment shows high anti-tumor effects. Based on these findings, clinical development for ⁶⁴Cu-ATSM internal radiotherapy is expected. Therefore, this paper is prepared to propose the timing to release a patient administered ⁶⁴Cu-ATSM from dedicated internal radiotherapy rooms to protect the general public and carers from the radiation. The special consideration for the radiation protection is also proposed to treat patients in the normal ward after the administration of ⁶⁴Cu-ATSM.

In late years, in ¹²³I-Metaiodobenzylguanidine (¹²³I-MIBG), it was established in cardiac sympathetic nerve functional disorder as objective evaluable inspection, and the heart/mediastinum ratio (the H/M ratio) in the planar image and fixed-quantity indexes including wash-out rate were unified by Nakajima and others. The H/M ratio brings the information that is useful for a heart failure disease severity evaluation, a prognosis, a therapeutic effect judgment. On the other hand, the issue of difference revision between the institutions with the semiconductor γ camera which has begun to be introduced in an own country remains. We developed the H/M ratio revision method in a semiconductor γ camera and an Anger scintillation camera this time and inspected it. I was able to be standardized using the H/M correction function that I obtained in this study.

This survey was performed to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2016 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. The reply was obtained from 977 institutions among 1,235 to which the questionnaire had been sent. Nine cases of adverse reactions were reported. A total of 1,052,650 radiopharmaceutical administrations was reported. The incidence of adverse reactions per 100,000 cases was 0.9. No case of deficient products was reported.